Jazz Pharmaceuticals plc (JAZZ) entered a merger agreement on March 5, 2025, to acquire Chimerix, Inc. (CMRX) through an all-cash tender offer valued at $935 million, expanding its presence in the rare oncology space.
Under this agreement, Jazz will commence an all-cash tender offer to acquire all outstanding shares of Chimerix’s common stock, whereby Chimerix shareholders will be offered $8.55 per share in cash, representing a premium of 72.38% from the stock’s last close.